- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06591286
실시간 연속 혈당 모니터링 시스템이 병원에서 가정으로의 이행적 혈당 조절에 미치는 영향
실시간 연속 혈당 모니터링 시스템이 인슐린 치료를 받는 제2형 당뇨병 환자의 병원에서 가정으로의 이행적 혈당 조절 및 자기효능감에 미치는 영향
Glucose monitoring is an important part of self-management for patients with diabetes. The results of glucose monitoring not only help to assess the degree of glucose metabolism disorders in patients, but also help physicians to make clinical decisions and guide patients in self-management. Despite extensive efforts and advances in diabetes management during hospitalization, glucose control after patients is discharged home remains a challenge. This trial aims to explore the effect of real-time continuous glucose monitoring (RT-CGM) system compared to self-monitoring of blood glucose (SMBG) group on glucose and self-efficacy of type 2 diabetes patients treated with insulin after discharge from the hospital.
연구 개요
상세 설명
Glycemic management of patients with diabetes after discharge home is extremely challenging, especially for those requiring insulin therapy. The use of a real-time continuous glucose monitoring (RT-CGM) system may improve glycemic control and self-efficacy in patients with type 2 diabetes treated with insulin after discharge from the hospital.
One hundred and fifty insulin-treated adults with type 2 diabetes were randomly assigned to receive either RT-CGM or self-monitoring of blood glucose (SMBG) at hospital discharge for a 12-week monitoring intervention and a 36-week follow-up.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, 중국, 200233
- Shanghai 6th People's Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- 18 years old ≤ age ≤ 80 years old.
- Type 2 diabetes admitted to Department of Endocrinology and Metabolism.
- 8% ≤ HbA1c ≤ 12% in the last 1 month.
- Insulin therapy within 1 month of planned discharge from hospital.
- Frequency of self-monitoring of blood glucose <4 times per week and no use of real-time continuous glucose monitoring system in the 3 months prior to hospitalisation.
- Willing and able to provide written informed consent and comply with the requirements of this study.
Exclusion Criteria:
- Oral steroid hormone therapy.
- Patients with acute complications of diabetes (including Diabetic ketoacidosis, hyperglycemia and hyperosmolality, Lactic acidosis)
- Patients with severe liver disease (alanine aminotransferase or glutamine aminotransferase exceeding more than three times the upper limit of normal).
- Patients with severe kidney injury or end-stage renal disease (eGFR < 30 mL/min/1.73 m2).
- Participants were unable to tolerate tape adhesive around sensor placement area, or with medically documented allergy towards the adhesive (glue) of plasters, or with serious skin diseases (e.g. psoriasis vulgaris, bacterial skin diseases) around sensor placement area.
- Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.
- Pregnant, breastfeeding, women of childbearing age who are unwilling to use contraception during the study period.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Intervention group
The intervention group (75 cases) will wear real-time CGM to monitor blood glucose for 12 weeks, followed by 36 weeks of follow-up. |
This group of patients will wear RT-CGM for blood glucose monitoring for three months. |
|
다른: Control group
The control group (75 cases) is self-monitored by traditional SMBG for 12 weeks at a frequency of no less than 4 times a week, followed by 36 weeks of follow-up. |
This group of patients will use a a fingertip glucose meter for blood glucose monitoring for three months, and the monitoring frequency was not less than 4 times per week. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Time in range (3.9~10.0mmol/L, %)
기간: 12 weeks
|
Percentage of time within glucose level of 3.9-10.0 mmol/L (70-180 mg/dL) measured by CGM. |
12 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
HbA1c (%)
기간: 4weeks, 8weeks, 12 weeks, 24weeks, 48weeks
|
Glycated hemoglobin (%) |
4weeks, 8weeks, 12 weeks, 24weeks, 48weeks
|
|
Time in range (3.9~10.0mmol/L, %)
기간: 4weeks, 8weeks, 24weeks, 48 weeks
|
Percentage of time within glucose level of 3.9-10.0 mmol/L (70-180 mg/dL) measured by CGM. |
4weeks, 8weeks, 24weeks, 48 weeks
|
|
Time above range (>10.0mmol/L, %)
기간: 4weeks, 8weeks, 12 weeks, 24weeks, 48weeks
|
Percentage of time above glucose level of 10.0 mmol/L (180 mg/dL) measured by CGM. |
4weeks, 8weeks, 12 weeks, 24weeks, 48weeks
|
|
Time below range (<3.9mmol/L, %)
기간: 4weeks, 8weeks, 12 weeks, 24weeks, 48weeks
|
Percentage of time below glucose level of 3.9 mmol/L (70 mg/dL) measured by CGM. |
4weeks, 8weeks, 12 weeks, 24weeks, 48weeks
|
|
Coefficient of variation (CV)
기간: 4weeks, 8weeks, 12 weeks, 24weeks, 48weeks
|
Standard deviation divided by mean glucose level measured by CGM. |
4weeks, 8weeks, 12 weeks, 24weeks, 48weeks
|
|
Standard deviation (SD)
기간: 4weeks, 8weeks, 12 weeks, 24weeks, 48weeks
|
Standard deviation of blood glucose measurements during CGM. |
4weeks, 8weeks, 12 weeks, 24weeks, 48weeks
|
|
Mean amplitude of glycemic excursions (MAGE)
기간: 4weeks, 8weeks, 12 weeks, 24weeks, 48weeks
|
Mean amplitude of glycemic excursions (MAGE) is the average value of all amplitude of glycemic excursions. |
4weeks, 8weeks, 12 weeks, 24weeks, 48weeks
|
|
Diabetes management self-efficacy
기간: 4weeks, 8weeks, 12 weeks, 24weeks, 48weeks
|
The Chinese version of Diabetes Management Self-efficacy Scale (DMSES) is used to evaluate the patients' self-efficacy |
4weeks, 8weeks, 12 weeks, 24weeks, 48weeks
|
|
Diabetes Self Care Activities
기간: 4weeks, 8weeks, 12 weeks, 24weeks, 48weeks
|
The Chinese version of Summary of Diabetes Self Care Activities (SDSCA) is used to evaluate the patients' self-efficacy |
4weeks, 8weeks, 12 weeks, 24weeks, 48weeks
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Jian Zhou, Dr., Shanghai 6th People's Hospital
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
기타 연구 ID 번호
- RT20240903
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .